Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures

Michael Rogawski, MD, PhD

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This episode, "FDA Approves Diazepam Buccal Film for Pediatric Seizures," features an exclusive interview with Michael Rogawski, MD, PhD, an epilepsy expert, who sat down to discuss the significance of the FDA approval of diazepam buccal film (Libervant; Aquestive Therapeutics) as a new treatment for pediatric patients with intermittent, stereotypic episodes of seizure activity. Rogawski, a distinguished professor of neurology and pharmacology at the University of California Davis Health Medical Center, provided insight on what the decision means for patients and clinicians alike. In addition, he spoke on the significance of having a new administration route for diazepam, the safety and feasibility of diazepam buccal film, and some of the major points of emphasis from its clinical program.

For more of NeurologyLive's coverage of givinostat's approval, head here: FDA approves diazepam for seizure clusters in patients 2 to 5 years

EPISODE BREAKDOWN

• 0:20 – Diazepam buccal film approved for intermittent seizures in pediatrics
• 2:00 – Michael Rogawski, MD, PhD, giving reaction to the approval
• 4:10 – Flexibility with multiple diazepam administration routes
• 6:55 – Rogawski on the safety of diazepam buccal film amid high need
• 12:30 – Notable takeaways from the diazepam buccal film trial program

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Aquestive Therapeutics receives US FDA Approval and market access for Libervant (diazepam) buccal film in pediatric patients ages 2 to 5 and provides update on Anaphylm (epinephrine) sublingual film. News release. Aquestive Therapeutics. April 29, 2024. Accessed April 31, 2024. https://finance.yahoo.com/news/aquestive-therapeutics-receives-u-fda-110000681.html